Wall Street opens mixed as US-China trade talks begin
Top officials from both countries have kicked off discussions at London's Lancaster House, looking to address disagreements around a preliminary trade agreement struck last month that had briefly cooled tensions between the world's largest economies.
The meeting, which could run into Tuesday, comes four days after US President Donald Trump and Chinese leader Xi Jinping spoke by phone, their first direct interaction since Trump's January 20 inauguration.
The leaders had, however, left key issues unresolved.
"The talks will have to go on for some time before we decide whether or not there's actual progress being made. However, most investors remain hopeful that there will be some positive results," said Peter Andersen, founder at Andersen Capital Management.
White House economic adviser Kevin Hassett told CNBC in an interview on Monday the US trade negotiators are seeking a handshake in London to seal an agreement struck by Trump and Xi to allow the export of China's rare earth minerals and magnets to the United States.
Hopes of more trade deals between the US and its major trading partners, along with upbeat earnings and tame inflation data, helped US equities rally in May, with the S&P 500 and the tech-heavy Nasdaq notching their best monthly gains since November 2023.
The S&P 500 remains a little more than 2.0 per cent below all-time highs touched in February while the Nasdaq is about 3.0 per cent below its record peaks reached in December.
Major data releases this week include readings on May consumer prices and initial jobless claims.
While investors widely expect the Federal Reserve to keep interest rates unchanged next week, focus will be on any signs of pick-up in inflation as Trump's tariffs risk raising price pressures.
In early trading on Monday, the Dow Jones Industrial Average fell 129.75 points, or 0.30 per cent, to 42,633.12, the S&P 500 lost 0.32 points, or 0.01 per cent, to 6,000.04 and the Nasdaq Composite gained 44.81 points, or 0.23 per cent, to 19,574.76.
Seven of the 11 major S&P 500 sub-sectors fell, with healthcare stocks, down 0.6 per cent, declining the most.
On the flip side, information technology stocks advanced 0.6 per cent.
Most megacap and growth stocks were mixed.
Tesla shares edged 0.5 per cent lower after brokerage Baird downgraded the stock to "neutral".
Nvidia gained 1.3 per cent.
Warner Bros Discovery shares jumped 9.5 per cent, the most on the S&P 500, after the company said it would separate its studios and streaming business from its fading cable television networks.
Robinhood Markets fell 7.4 per cent after S&P Dow Jones Indices left S&P 500 constituents unchanged in its latest rebalancing, following recent speculation that the online brokerage would be added to the benchmark index.
Merck rose 1.1 per cent after the drug maker's oral cholesterol pill succeeded in two late-stage studies.
Advancing issues outnumbered decliners by a 1.65-to-1 ratio on the NYSE and by a 1.44-to-1 ratio on the Nasdaq.
The S&P 500 posted 10 new 52-week highs and one new low while the Nasdaq Composite recorded 63 new highs and 27 new lows.
Wall Street's main indexes are mixed as investors watch a fresh round of US-China negotiations aimed at mending a trade rift that has rattled financial markets for much of the year.
Top officials from both countries have kicked off discussions at London's Lancaster House, looking to address disagreements around a preliminary trade agreement struck last month that had briefly cooled tensions between the world's largest economies.
The meeting, which could run into Tuesday, comes four days after US President Donald Trump and Chinese leader Xi Jinping spoke by phone, their first direct interaction since Trump's January 20 inauguration.
The leaders had, however, left key issues unresolved.
"The talks will have to go on for some time before we decide whether or not there's actual progress being made. However, most investors remain hopeful that there will be some positive results," said Peter Andersen, founder at Andersen Capital Management.
White House economic adviser Kevin Hassett told CNBC in an interview on Monday the US trade negotiators are seeking a handshake in London to seal an agreement struck by Trump and Xi to allow the export of China's rare earth minerals and magnets to the United States.
Hopes of more trade deals between the US and its major trading partners, along with upbeat earnings and tame inflation data, helped US equities rally in May, with the S&P 500 and the tech-heavy Nasdaq notching their best monthly gains since November 2023.
The S&P 500 remains a little more than 2.0 per cent below all-time highs touched in February while the Nasdaq is about 3.0 per cent below its record peaks reached in December.
Major data releases this week include readings on May consumer prices and initial jobless claims.
While investors widely expect the Federal Reserve to keep interest rates unchanged next week, focus will be on any signs of pick-up in inflation as Trump's tariffs risk raising price pressures.
In early trading on Monday, the Dow Jones Industrial Average fell 129.75 points, or 0.30 per cent, to 42,633.12, the S&P 500 lost 0.32 points, or 0.01 per cent, to 6,000.04 and the Nasdaq Composite gained 44.81 points, or 0.23 per cent, to 19,574.76.
Seven of the 11 major S&P 500 sub-sectors fell, with healthcare stocks, down 0.6 per cent, declining the most.
On the flip side, information technology stocks advanced 0.6 per cent.
Most megacap and growth stocks were mixed.
Tesla shares edged 0.5 per cent lower after brokerage Baird downgraded the stock to "neutral".
Nvidia gained 1.3 per cent.
Warner Bros Discovery shares jumped 9.5 per cent, the most on the S&P 500, after the company said it would separate its studios and streaming business from its fading cable television networks.
Robinhood Markets fell 7.4 per cent after S&P Dow Jones Indices left S&P 500 constituents unchanged in its latest rebalancing, following recent speculation that the online brokerage would be added to the benchmark index.
Merck rose 1.1 per cent after the drug maker's oral cholesterol pill succeeded in two late-stage studies.
Advancing issues outnumbered decliners by a 1.65-to-1 ratio on the NYSE and by a 1.44-to-1 ratio on the Nasdaq.
The S&P 500 posted 10 new 52-week highs and one new low while the Nasdaq Composite recorded 63 new highs and 27 new lows.
Wall Street's main indexes are mixed as investors watch a fresh round of US-China negotiations aimed at mending a trade rift that has rattled financial markets for much of the year.
Top officials from both countries have kicked off discussions at London's Lancaster House, looking to address disagreements around a preliminary trade agreement struck last month that had briefly cooled tensions between the world's largest economies.
The meeting, which could run into Tuesday, comes four days after US President Donald Trump and Chinese leader Xi Jinping spoke by phone, their first direct interaction since Trump's January 20 inauguration.
The leaders had, however, left key issues unresolved.
"The talks will have to go on for some time before we decide whether or not there's actual progress being made. However, most investors remain hopeful that there will be some positive results," said Peter Andersen, founder at Andersen Capital Management.
White House economic adviser Kevin Hassett told CNBC in an interview on Monday the US trade negotiators are seeking a handshake in London to seal an agreement struck by Trump and Xi to allow the export of China's rare earth minerals and magnets to the United States.
Hopes of more trade deals between the US and its major trading partners, along with upbeat earnings and tame inflation data, helped US equities rally in May, with the S&P 500 and the tech-heavy Nasdaq notching their best monthly gains since November 2023.
The S&P 500 remains a little more than 2.0 per cent below all-time highs touched in February while the Nasdaq is about 3.0 per cent below its record peaks reached in December.
Major data releases this week include readings on May consumer prices and initial jobless claims.
While investors widely expect the Federal Reserve to keep interest rates unchanged next week, focus will be on any signs of pick-up in inflation as Trump's tariffs risk raising price pressures.
In early trading on Monday, the Dow Jones Industrial Average fell 129.75 points, or 0.30 per cent, to 42,633.12, the S&P 500 lost 0.32 points, or 0.01 per cent, to 6,000.04 and the Nasdaq Composite gained 44.81 points, or 0.23 per cent, to 19,574.76.
Seven of the 11 major S&P 500 sub-sectors fell, with healthcare stocks, down 0.6 per cent, declining the most.
On the flip side, information technology stocks advanced 0.6 per cent.
Most megacap and growth stocks were mixed.
Tesla shares edged 0.5 per cent lower after brokerage Baird downgraded the stock to "neutral".
Nvidia gained 1.3 per cent.
Warner Bros Discovery shares jumped 9.5 per cent, the most on the S&P 500, after the company said it would separate its studios and streaming business from its fading cable television networks.
Robinhood Markets fell 7.4 per cent after S&P Dow Jones Indices left S&P 500 constituents unchanged in its latest rebalancing, following recent speculation that the online brokerage would be added to the benchmark index.
Merck rose 1.1 per cent after the drug maker's oral cholesterol pill succeeded in two late-stage studies.
Advancing issues outnumbered decliners by a 1.65-to-1 ratio on the NYSE and by a 1.44-to-1 ratio on the Nasdaq.
The S&P 500 posted 10 new 52-week highs and one new low while the Nasdaq Composite recorded 63 new highs and 27 new lows.
Wall Street's main indexes are mixed as investors watch a fresh round of US-China negotiations aimed at mending a trade rift that has rattled financial markets for much of the year.
Top officials from both countries have kicked off discussions at London's Lancaster House, looking to address disagreements around a preliminary trade agreement struck last month that had briefly cooled tensions between the world's largest economies.
The meeting, which could run into Tuesday, comes four days after US President Donald Trump and Chinese leader Xi Jinping spoke by phone, their first direct interaction since Trump's January 20 inauguration.
The leaders had, however, left key issues unresolved.
"The talks will have to go on for some time before we decide whether or not there's actual progress being made. However, most investors remain hopeful that there will be some positive results," said Peter Andersen, founder at Andersen Capital Management.
White House economic adviser Kevin Hassett told CNBC in an interview on Monday the US trade negotiators are seeking a handshake in London to seal an agreement struck by Trump and Xi to allow the export of China's rare earth minerals and magnets to the United States.
Hopes of more trade deals between the US and its major trading partners, along with upbeat earnings and tame inflation data, helped US equities rally in May, with the S&P 500 and the tech-heavy Nasdaq notching their best monthly gains since November 2023.
The S&P 500 remains a little more than 2.0 per cent below all-time highs touched in February while the Nasdaq is about 3.0 per cent below its record peaks reached in December.
Major data releases this week include readings on May consumer prices and initial jobless claims.
While investors widely expect the Federal Reserve to keep interest rates unchanged next week, focus will be on any signs of pick-up in inflation as Trump's tariffs risk raising price pressures.
In early trading on Monday, the Dow Jones Industrial Average fell 129.75 points, or 0.30 per cent, to 42,633.12, the S&P 500 lost 0.32 points, or 0.01 per cent, to 6,000.04 and the Nasdaq Composite gained 44.81 points, or 0.23 per cent, to 19,574.76.
Seven of the 11 major S&P 500 sub-sectors fell, with healthcare stocks, down 0.6 per cent, declining the most.
On the flip side, information technology stocks advanced 0.6 per cent.
Most megacap and growth stocks were mixed.
Tesla shares edged 0.5 per cent lower after brokerage Baird downgraded the stock to "neutral".
Nvidia gained 1.3 per cent.
Warner Bros Discovery shares jumped 9.5 per cent, the most on the S&P 500, after the company said it would separate its studios and streaming business from its fading cable television networks.
Robinhood Markets fell 7.4 per cent after S&P Dow Jones Indices left S&P 500 constituents unchanged in its latest rebalancing, following recent speculation that the online brokerage would be added to the benchmark index.
Merck rose 1.1 per cent after the drug maker's oral cholesterol pill succeeded in two late-stage studies.
Advancing issues outnumbered decliners by a 1.65-to-1 ratio on the NYSE and by a 1.44-to-1 ratio on the Nasdaq.
The S&P 500 posted 10 new 52-week highs and one new low while the Nasdaq Composite recorded 63 new highs and 27 new lows.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
7NEWS
37 minutes ago
- 7NEWS
7NEWS The Issue: Why Trump's latest veiled threat could spell trouble for the pride of Australia
It was a telling measure of the value Australians put in the country's 77-year-old Pharmaceutical Benefits Scheme. In mid March, as the Albanese government looked for an issue to give it impetus for a soon-to-be-called election, it turned to the PBS; loved in Australia - and loathed by Pharmaceutical makers abroad - for delivering medicines at little more than one quarter the cost paid by Americans. Prime Minister Albanese announced, if reelected, he'd reduce the scheme's cap on prescriptions, from $31.60 to just $25. Opposition leader Peter Dutton immediately backed the plan. 'We support affordable medicines,' he told radio 2GB. On complaints from US pharmaceutical companies about the PBS, the Prime Minister seized on the chance for a fight. The PBS, he said was 'a monument to the fairness at the heart of Australian life and we don't negotiate our values.' The PBS is political gold. Supporting it is a 'no brainer' for a federal politician. Yet, five months on that threat from the US, has only intensified and it may yet test Australia's love for the scheme. For President Donald Trump, high prescription drug costs in America have become a cause. Loading content... Last month, the White House announced the President had written to 17 drug company CEOs demanding guarantees 'they will not offer other developed nations better prices for new drugs than prices offered in the United States.' According to a Trump White House fact sheet, 'Americans are subsidising drug-manufacturer profits and foreign health systems.' The statement did not mention Australia's PBS, but if the White House staff had wanted an example, it would have been an obvious candidate. 'The PBS is a cornerstone of our Medicare system' according to Medicines Australia CEO, Liz de Somer, though that's where her applause for the scheme ends. Medicines Australia is the industry body representing many of the same pharmaceutical giants now targeted by the Trump White House. According to Liz de Somer 'we're lagging behind other countries in the time it takes to make new medicines available on the PBS.' 'We are now taking an average of 466 days for a new innovative medicine to be listed on the PBS, and that's after it's already been deemed safe and effective by the Therapeutic Goods Administration.' 'We know these drugs are safe, we know they're effective, but the government has not yet decided to purchase them and make them subsidised for patients. They take too long.' Medicines Australia wants the 466 days average drug listing time, reduced dramatically - to just sixty days. That would likely mean dramatically reducing the time taken by the government and companies to negotiate a price for their medicines. The end result could easily be a bigger bill for the Australian taxpayer. Currently, the PBS costs about $14 billion a year to run. Of course, there is a human cost to delaying approval for medicines. Medicines Australia points to the 'many, many cancer medicines that are not available for patients' in Australia. According to Liz de Somer: 'We are getting one in four innovations listed on our PBS at the moment. That's not good enough.' 'We know that people are waiting for these medicines. We know that they can see they're available in other countries, and they don't understand why they're not made available here.' There is an obvious profit motive for pharmaceutical companies in getting listed sooner and selling their product more quickly, but delays in the system have a human cost. The Albanese government is currently considering recommendations to reform the scheme including measures designed to speed the process.
The Advertiser
6 hours ago
- The Advertiser
Honda Australia not worried about Chinese competition
Honda Australiasays it has what it takes to compete with the growing number of Chinese brands in our market, as it looks to rebuild after several tough sales years. While Honda is pitched – and priced – as a more premium brand than many Japanese rivals, it's facing increased competition from new brands from China. Chinese automakers are aiming ever higher, expanding beyond the cheap and cheerful offerings they're known for to more premium products – witness the introduction of Geely's Zeekr marque, MG offering products from the IM Motors premium brand, GWM offering pricier Tank SUVs, and BYD readying its more luxurious Denza offshoot for Australia. But while Chinese brands are aiming upmarket, Honda Australia says it will focus on its plan regardless of who enters the local scene, with managing director Rob Thorp confident the automaker is on track for growth in Australia. CarExpert can save you thousands on a new car. Click here to get a great deal. "It's a competitive landscape – so whether it is the Chinese competitors, or the Koreans or the Germans – or whatever it may be, that just becomes the competitive landscape we have to deal with," Mr Thorp told CarExpert. "It's a free market, they've got the right opportunity to compete here, it is what it is. "I think for us, we're very clear on our proposition in the markets and what our competitive strengths are. I think the challenge we have is to ensure that enough consumers know that." What are those strengths the Honda boss believes will hold the brand in good shape in Australia over the next decade? "I think of it from the quality of the product that you see, the quality of the customer care and service you receive, the longevity of the models and the relationship we have with you during the ownership period," he explained. "So we're very comfortable we've got the ingredients to be successful in this market – but they're competitors, whatever and wherever they come from – that's just the environment we have to work in." The Japanese brand is expanding its hybrid lineup, which will include the introduction of the hybrid-powered Prelude sports car here next year, and plans to launch its first electric vehicle (EV) before the end of 2026, too. It has, however, ruled out bringing its luxury brand sold overseas, Acura, to local showrooms. Honda posted its lowest sales on record in this country in 2022 and 2023, following the move to a fixed-price agency model, a reduction in the number of dealers in its network, and the discontinuation of more affordable products like the Jazz. The number of brands in Australia has continue to increase, making our market – already saturated given the number of brands competing for sales of only 1.2 million vehicles each year – even more cut-throat. It led chief operating officer of Chery-owned Omoda Jaecoo, Roy Muñoz, to recently declare more brands benefited new-car buyers and only improved showroom offerings through an ultra-competitive climate. MORE: Honda Australia's first EV to launch in 2026, but what will it be? MORE: Australia doesn't have too many car brands, says one of its newest arrivals Content originally sourced from: Honda Australiasays it has what it takes to compete with the growing number of Chinese brands in our market, as it looks to rebuild after several tough sales years. While Honda is pitched – and priced – as a more premium brand than many Japanese rivals, it's facing increased competition from new brands from China. Chinese automakers are aiming ever higher, expanding beyond the cheap and cheerful offerings they're known for to more premium products – witness the introduction of Geely's Zeekr marque, MG offering products from the IM Motors premium brand, GWM offering pricier Tank SUVs, and BYD readying its more luxurious Denza offshoot for Australia. But while Chinese brands are aiming upmarket, Honda Australia says it will focus on its plan regardless of who enters the local scene, with managing director Rob Thorp confident the automaker is on track for growth in Australia. CarExpert can save you thousands on a new car. Click here to get a great deal. "It's a competitive landscape – so whether it is the Chinese competitors, or the Koreans or the Germans – or whatever it may be, that just becomes the competitive landscape we have to deal with," Mr Thorp told CarExpert. "It's a free market, they've got the right opportunity to compete here, it is what it is. "I think for us, we're very clear on our proposition in the markets and what our competitive strengths are. I think the challenge we have is to ensure that enough consumers know that." What are those strengths the Honda boss believes will hold the brand in good shape in Australia over the next decade? "I think of it from the quality of the product that you see, the quality of the customer care and service you receive, the longevity of the models and the relationship we have with you during the ownership period," he explained. "So we're very comfortable we've got the ingredients to be successful in this market – but they're competitors, whatever and wherever they come from – that's just the environment we have to work in." The Japanese brand is expanding its hybrid lineup, which will include the introduction of the hybrid-powered Prelude sports car here next year, and plans to launch its first electric vehicle (EV) before the end of 2026, too. It has, however, ruled out bringing its luxury brand sold overseas, Acura, to local showrooms. Honda posted its lowest sales on record in this country in 2022 and 2023, following the move to a fixed-price agency model, a reduction in the number of dealers in its network, and the discontinuation of more affordable products like the Jazz. The number of brands in Australia has continue to increase, making our market – already saturated given the number of brands competing for sales of only 1.2 million vehicles each year – even more cut-throat. It led chief operating officer of Chery-owned Omoda Jaecoo, Roy Muñoz, to recently declare more brands benefited new-car buyers and only improved showroom offerings through an ultra-competitive climate. MORE: Honda Australia's first EV to launch in 2026, but what will it be? MORE: Australia doesn't have too many car brands, says one of its newest arrivals Content originally sourced from: Honda Australiasays it has what it takes to compete with the growing number of Chinese brands in our market, as it looks to rebuild after several tough sales years. While Honda is pitched – and priced – as a more premium brand than many Japanese rivals, it's facing increased competition from new brands from China. Chinese automakers are aiming ever higher, expanding beyond the cheap and cheerful offerings they're known for to more premium products – witness the introduction of Geely's Zeekr marque, MG offering products from the IM Motors premium brand, GWM offering pricier Tank SUVs, and BYD readying its more luxurious Denza offshoot for Australia. But while Chinese brands are aiming upmarket, Honda Australia says it will focus on its plan regardless of who enters the local scene, with managing director Rob Thorp confident the automaker is on track for growth in Australia. CarExpert can save you thousands on a new car. Click here to get a great deal. "It's a competitive landscape – so whether it is the Chinese competitors, or the Koreans or the Germans – or whatever it may be, that just becomes the competitive landscape we have to deal with," Mr Thorp told CarExpert. "It's a free market, they've got the right opportunity to compete here, it is what it is. "I think for us, we're very clear on our proposition in the markets and what our competitive strengths are. I think the challenge we have is to ensure that enough consumers know that." What are those strengths the Honda boss believes will hold the brand in good shape in Australia over the next decade? "I think of it from the quality of the product that you see, the quality of the customer care and service you receive, the longevity of the models and the relationship we have with you during the ownership period," he explained. "So we're very comfortable we've got the ingredients to be successful in this market – but they're competitors, whatever and wherever they come from – that's just the environment we have to work in." The Japanese brand is expanding its hybrid lineup, which will include the introduction of the hybrid-powered Prelude sports car here next year, and plans to launch its first electric vehicle (EV) before the end of 2026, too. It has, however, ruled out bringing its luxury brand sold overseas, Acura, to local showrooms. Honda posted its lowest sales on record in this country in 2022 and 2023, following the move to a fixed-price agency model, a reduction in the number of dealers in its network, and the discontinuation of more affordable products like the Jazz. The number of brands in Australia has continue to increase, making our market – already saturated given the number of brands competing for sales of only 1.2 million vehicles each year – even more cut-throat. It led chief operating officer of Chery-owned Omoda Jaecoo, Roy Muñoz, to recently declare more brands benefited new-car buyers and only improved showroom offerings through an ultra-competitive climate. MORE: Honda Australia's first EV to launch in 2026, but what will it be? MORE: Australia doesn't have too many car brands, says one of its newest arrivals Content originally sourced from: Honda Australiasays it has what it takes to compete with the growing number of Chinese brands in our market, as it looks to rebuild after several tough sales years. While Honda is pitched – and priced – as a more premium brand than many Japanese rivals, it's facing increased competition from new brands from China. Chinese automakers are aiming ever higher, expanding beyond the cheap and cheerful offerings they're known for to more premium products – witness the introduction of Geely's Zeekr marque, MG offering products from the IM Motors premium brand, GWM offering pricier Tank SUVs, and BYD readying its more luxurious Denza offshoot for Australia. But while Chinese brands are aiming upmarket, Honda Australia says it will focus on its plan regardless of who enters the local scene, with managing director Rob Thorp confident the automaker is on track for growth in Australia. CarExpert can save you thousands on a new car. Click here to get a great deal. "It's a competitive landscape – so whether it is the Chinese competitors, or the Koreans or the Germans – or whatever it may be, that just becomes the competitive landscape we have to deal with," Mr Thorp told CarExpert. "It's a free market, they've got the right opportunity to compete here, it is what it is. "I think for us, we're very clear on our proposition in the markets and what our competitive strengths are. I think the challenge we have is to ensure that enough consumers know that." What are those strengths the Honda boss believes will hold the brand in good shape in Australia over the next decade? "I think of it from the quality of the product that you see, the quality of the customer care and service you receive, the longevity of the models and the relationship we have with you during the ownership period," he explained. "So we're very comfortable we've got the ingredients to be successful in this market – but they're competitors, whatever and wherever they come from – that's just the environment we have to work in." The Japanese brand is expanding its hybrid lineup, which will include the introduction of the hybrid-powered Prelude sports car here next year, and plans to launch its first electric vehicle (EV) before the end of 2026, too. It has, however, ruled out bringing its luxury brand sold overseas, Acura, to local showrooms. Honda posted its lowest sales on record in this country in 2022 and 2023, following the move to a fixed-price agency model, a reduction in the number of dealers in its network, and the discontinuation of more affordable products like the Jazz. The number of brands in Australia has continue to increase, making our market – already saturated given the number of brands competing for sales of only 1.2 million vehicles each year – even more cut-throat. It led chief operating officer of Chery-owned Omoda Jaecoo, Roy Muñoz, to recently declare more brands benefited new-car buyers and only improved showroom offerings through an ultra-competitive climate. MORE: Honda Australia's first EV to launch in 2026, but what will it be? MORE: Australia doesn't have too many car brands, says one of its newest arrivals Content originally sourced from:
AU Financial Review
14 hours ago
- AU Financial Review
Dow lifts on UnitedHealth, consumer sentiment unexpectedly falls
The Dow Jones reset a record high, while both the S&P 500 and Nasdaq Composite slipped in the final trading session of the week in New York. UnitedHealth's shares leapt more than 10 per cent after Berkshire Hathaway lifted its stake in the health insurer. That helped the Dow offset weakness in Cisco, 3M and Goldman Sachs.
